Zhejiang inCarey Pharmaceutical Technology Co., Ltd. announced that it has completed a US$30 million series B+ round of financing, with the exclusive investment of Long Hill Capital. China Renaissance Capital acted as the exclusive financial advisor for this round of financing.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
